Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Anxiety

MalaCards integrated aliases for Anxiety:

Name: Anxiety 57 12 29 6 43 40 17 72
Anxiety Disorders 55 44 72
Anxiety Disorder 12 15 17
Anxiety State 12 72
Anxiety Neurosis 72
Anxieties 15


External Ids:

Disease Ontology 12 DOID:2030
OMIM 57 607834
MeSH 44 D001008
NCIt 50 C2878
SNOMED-CT 68 65673007
ICD10 33 F41.8 F41.9
MedGen 42 C0003467
UMLS 72 C0003467 C0003469 C0700613 more

Summaries for Anxiety

OMIM : 57 Human personality is shaped by genetic and environmental factors, and evidence suggests that the genetic component is highly complex, polygenic, and epistatic. Genetic factors are thought to contribute to 40 to 60% of trait variance. Molecular genetics has tried to identify specific genes for quantitative traits, called quantitative trait loci (QTLs). The QTL concept suggests that complex personality traits or dimensions are not attributable to single genes, but to multiple interacting genes (Reif and Lesch, 2003). Fullerton et al. (2003) stated that psychologists were in agreement that the wide variation in human personalities can be explained by a small number of personality factors, including neuroticism (a measure of emotional stability), which manifests at one extreme as anxiety, depression, moodiness, low self-esteem, and diffidence. They cited a number of studies that had described a relationship between high scores on measures of neuroticism and major depressive disorder. They also noted that theoretical studies had suggested that large samples of randomly ascertained sibs could be used to ascertain phenotypically extreme individuals and thereby increase power to detect genetic linkage in complex traits. See also panic disorder (PAND1; 167870), which is a subtype of anxiety disorder. (607834)

MalaCards based summary : Anxiety, also known as anxiety disorders, is related to generalized anxiety disorder and phobic disorder, and has symptoms including agitation, sleeplessness and mental and behavioral signs and symptoms. An important gene associated with Anxiety is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Tangerine and Moxonidine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and breast, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

MedlinePlus : 43 Fear and anxiety are part of life. You may feel anxious before you take a test or walk down a dark street. This kind of anxiety is useful - it can make you more alert or careful. It usually ends soon after you are out of the situation that caused it. But for millions of people in the United States, the anxiety does not go away, and gets worse over time. They may have chest pains or nightmares. They may even be afraid to leave home. These people have anxiety disorders. Types include Panic disorder Obsessive-compulsive disorder Post-traumatic stress disorder Phobias Generalized anxiety disorder Treatment can involve medicines, therapy or both. NIH: National Institute of Mental Health

Wikipedia : 75 Anxiety is an emotion characterized by an unpleasant state of inner turmoil, often accompanied by... more...

Related Diseases for Anxiety

Diseases related to Anxiety via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1245)
# Related Disease Score Top Affiliating Genes
1 generalized anxiety disorder 35.1 TSPO TPH1 SLC6A4 MAOA HTR1A CRHR1
2 phobic disorder 34.5 SLC6A4 MAOA HTR1A
3 social phobia 34.2 SLC6A4 MAOA HTR1A
4 agoraphobia 33.8 SLC6A4 MAOA HTR1A CCKBR
5 panic disorder 33.6 TSPO TPH2 SLC6A4 MAOA HTR1A CRH
6 bipolar disorder 33.4 TPH1 SLC6A4 HTR1A BDNF
7 eating disorder 33.3 SLC6A4 HTR2C CRH CNR1 BDNF
8 post-traumatic stress disorder 33.1 SLC6A4 NR3C1 MAOA CRH CNR1 BDNF
9 obsessive-compulsive disorder 32.9 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR1A
10 depression 32.6 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
11 attention deficit-hyperactivity disorder 32.6 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR1A
12 major depressive disorder 32.3 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
13 avoidant personality disorder 32.2 TPH1 SLC6A4 MAOA
14 acth-secreting pituitary adenoma 32.1 NR3C1 CRH
15 personality disorder 32.0 TPH1 SLC6A4 MAOA HTR2C HTR1A BDNF
16 substance abuse 31.9 SLC6A4 MAOA CYP2D6 BDNF
17 postpartum depression 31.7 SLC6A4 MAOA CRH BDNF
18 bipolar i disorder 31.7 SLC6A4 HTR2C HTR1A BDNF
19 dysthymic disorder 31.6 SLC6A4 MAOA
20 conduct disorder 31.6 TPH1 SLC6A4 MAOA
21 anorexia nervosa 31.6 SLC6A4 CRH BDNF
22 tobacco addiction 31.5 TPH1 SLC6A4 MAOA
23 mood disorder 31.5 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
24 mental depression 31.5 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
25 oppositional defiant disorder 31.5 TPH2 SLC6A4 MAOA
26 irritable bowel syndrome 31.5 TPH1 SLC6A4 CRHR1 CRH
27 psychotic disorder 31.4 TPH1 SLC6A4 HTR2C HTR1A CYP2D6 BDNF
28 premature ejaculation 31.4 SLC6A4 HTR2C HTR1A
29 drug dependence 31.4 SLC6A4 OPRL1 CRH CNR1 BDNF
30 withdrawal disorder 31.4 TSPO CRH CNR1
31 fibromyalgia 31.4 TSPO SLC6A4 CRH
32 atypical depressive disorder 31.3 SLC6A4 MAOA CRH
33 substance dependence 31.2 SLC6A4 MAOA CYP2D6 CNR1 BDNF
34 migraine with or without aura 1 31.2 TPH1 SLC6A4 NPS MAOA HTR2C HTR1A
35 paranoid schizophrenia 31.1 TPH2 SLC6A4 MAOA BDNF
36 alcohol dependence 31.0 TSPO TPH2 TPH1 SLC6A4 OPRL1 MAOA
37 endogenous depression 31.0 TPH1 SLC6A4 NR3C1 MAOA HTR1A CRHR1
38 borderline personality disorder 31.0 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
39 temporal lobe epilepsy 31.0 TSPO HTR1A BDNF
40 kleptomania 31.0 SLC6A4 MAOA HTR1A
41 disease of mental health 30.8 SLC6A4 NPS MAOA HTR2C HTR1A CYP2D6
42 psychosexual disorder 30.7 SLC6A4 HTR2C HTR1A
43 schizophrenia 30.7 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR1A
44 chronic fatigue syndrome 30.7 TPH2 SLC6A4 NR3C1 MAOA HTR1A CRH
45 schizophrenia 5 30.7 HTR2C HTR1A
46 cannabis abuse 30.6 CNR1 BDNF
47 amnestic disorder 30.6 TSPO HTR1A CNR1 BDNF
48 parkinson disease, late-onset 30.6 SLC6A4 MAOA HTR1A CYP2D6 CNR1 BDNF
49 dissociative amnesia 30.5 NPS HTR1A
50 sudden infant death syndrome 30.5 TPH2 TPH1 SLC6A4 MAOA HTR1A BDNF

Comorbidity relations with Anxiety via Phenotypic Disease Network (PDN): (show top 50) (show all 78)

Acute Cor Pulmonale Acute Cystitis
Acute Stress Disorder Adjustment Disorder
Allergic Rhinitis Atrophic Gastritis
Atypical Depressive Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Borderline Personality Disorder
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Chronic Pulmonary Heart Disease Chronic Rhinitis
Conn's Syndrome Conversion Disorder
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Gastroesophageal Reflux Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Histrionic Personality Disorder Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Hypochondriasis
Hypothyroidism Intermediate Coronary Syndrome
Intestinal Obstruction Iron Deficiency Anemia
Irritable Bowel Syndrome Labyrinthitis
Major Depressive Disorder Malignant Essential Hypertension
Meniere Disease Migraine with or Without Aura 1
Mitral Valve Disease Mood Disorder
Narcissistic Personality Disorder Obsessive-Compulsive Disorder

Graphical network of the top 20 diseases related to Anxiety:

Diseases related to Anxiety

Symptoms & Phenotypes for Anxiety

Clinical features from OMIM:


UMLS symptoms related to Anxiety:

agitation, sleeplessness, mental and behavioral signs and symptoms, nervousness, feeling tense, feeling jittery, anxiety symptoms

MGI Mouse Phenotypes related to Anxiety:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 BDNF CCKBR CNR1 CRH CRHR1 HTR1A
2 homeostasis/metabolism MP:0005376 10.17 BDNF CCKBR CNR1 CRH CRHR1 HTR1A
3 cardiovascular system MP:0005385 10.02 CCKBR CRHR1 HTR1A MAOA NR3C1 SLC6A4
4 nervous system MP:0003631 9.97 BDNF CCKBR CNR1 CRH CRHR1 HTR1A
5 integument MP:0010771 9.96 BDNF CCKBR CNR1 CRH HTR2C NR3C1
6 adipose tissue MP:0005375 9.91 CNR1 CRH HTR2C NR3C1 TPH1 TPH2
7 no phenotypic analysis MP:0003012 9.5 BDNF CNR1 CRH CRHR1 HTR1A NR3C1
8 normal MP:0002873 9.28 BDNF CNR1 CRH CRHR1 NR3C1 OPRL1

Drugs & Therapeutics for Anxiety

Drugs for Anxiety (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Tangerine Approved Phase 4
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
Trimebutine Approved Phase 4 39133-31-8
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
Drospirenone Approved Phase 4 67392-87-4 68873
Prucalopride Approved Phase 4 179474-81-8
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
Disulfiram Approved Phase 4 97-77-8 3117
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
Methyltestosterone Approved Phase 4 58-18-4 6010
Testosterone enanthate Approved Phase 4 315-37-7 9416
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
Ribavirin Approved Phase 4 36791-04-5 37542
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Butorphanol Approved, Illicit, Vet_approved Phase 4 58786-99-5, 42408-82-2 5361092
Desipramine Approved, Investigational Phase 4 50-47-5 2995
Lofexidine Approved, Investigational Phase 4 31036-80-3 30668
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
Nitrazepam Approved Phase 4 146-22-5 4506
Clozapine Approved Phase 4 5786-21-0 2818
Mianserin Approved, Investigational Phase 4 24219-97-4 4184
Flurazepam Approved, Illicit, Investigational Phase 4 17617-23-1 3393
Haloperidol Approved Phase 4 52-86-8 3559
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Desflurane Approved Phase 4 57041-67-5 42113
Nitric Oxide Approved Phase 4 10102-43-9 145068
Benzydamine Approved Phase 4 100-46-9, 642-72-8 7504
Ranibizumab Approved Phase 4 347396-82-1 459903
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
Iloperidone Approved Phase 4 133454-47-4 71360
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Bromfenac Approved Phase 4 91714-94-2 60726
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430

Interventional clinical trials:

(show top 50) (show all 8599)
# Name Status NCT ID Phase Drugs
1 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
2 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
4 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
5 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
6 Comparison of 2 Methods to Reduce Postoperative Pain in Children and a Comparison of 3 Methods of Preoperative Education Intervention to Reduce Anxiety in Children and Their Family Unknown status NCT00643032 Phase 4
7 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
8 Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
9 The Effect of Music Over the Tolerance to Colonoscopy ¿Does it Reduce the Discomfort, the Anxiety and the Need of Sedation? Multicentric Randomized Controlled Trial. Unknown status NCT01285284 Phase 4
10 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
11 Effects of a Probiotic Supplement on Symptoms of ADHD and Anxiety in Children Unknown status NCT02545634 Phase 4
12 The Short and Long Term Effects of Perioperative Pregabalin Use on Functional Rehabilitation, Pain Outcomes and Anxiety Following Total Hip Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial. Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
13 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
14 Phase 4 Study of The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung : A Randomized, Double Blind, Placebo-control Trial Unknown status NCT01362114 Phase 4 SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
15 Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy Unknown status NCT01121055 Phase 4 Lorazepam;Control
16 Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial Unknown status NCT02243826 Phase 4 50:50 mixture of nitrous oxide/oxygen
17 Effectiveness of Oral Midazolam for Sedation in Patients Undergoing Upper Gastrointestinal Endoscopy Unknown status NCT01990937 Phase 4 Oral midazolam
18 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol A) in Oral Surgery Patients B) in General Dentistry Patients C) in Colonoscopy Patients Unknown status NCT00355693 Phase 4
19 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
20 Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema": MIMO Trial Unknown status NCT02856698 Phase 4 Midazolam;Morphine
21 A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
22 A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease Unknown status NCT03151382 Phase 4 Tandospirone Citrate;Donepezil Hydrochloride
23 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
24 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
25 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
26 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
27 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
28 Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
29 The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
30 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial Unknown status NCT00866866 Phase 4 N-Acetyl Cysteine;Placebo
31 Early Pharmacological Intervention With Diazepam in the Emergency Room Setting to Prevent Posttraumatic Stress Disorder (PTSD). Unknown status NCT01221883 Phase 4 Diazepam
32 The Role of Inflammatory and Stress Response in the Pathogenesis of Cognitive Dysfunction After Cardiac Surgery Unknown status NCT02767713 Phase 4 Dexamethasone
33 Comparison Between the Analgesic Affects of Tramadol® and "Verbal Anesthesia" on Pain Management Associated With the Insertion of Jaydess® in Nulliparous Women Unknown status NCT02706509 Phase 4 Tramadol
34 Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery Unknown status NCT01155804 Phase 4
35 A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children - a Double- Blind Randomised Controlled Trial Unknown status NCT02459509 Phase 4 Dexmedetomidine
36 Does Massage With or Without Aromatherapy Reduce Infant's Distress After Craniofacial Surgery? A Randomized Controlled Trial Unknown status NCT00624637 Phase 4
37 The Effect of Intracervical Lidocaine Versus Intramuscular Diclofenac for Pain Relief During Hysterosalpingography Among Infertile Women In A Tertiary Hospital In Kano: A Randomized Controlled Trial Unknown status NCT02918812 Phase 4 Intracervical lidocaine;Intramuscular Diclofenac
38 Impact of VSL#3 on Infants Colics as Assessed by Average Crying Time Unknown status NCT01869426 Phase 4
39 Randomized, Multicentric and Prospective Clinical Trial to Check the Cost-effectiveness of Corifollitropin Alfa vs. Recombinant FSH and/or HP-hMG Unknown status NCT02213627 Phase 4 Corifollitropin alfa;Recombinant FSH;HP-hMG
40 An Evaluation of the Paracervical Block for Pain Control in First Trimester Surgical Abortion Unknown status NCT01094366 Phase 4
41 Pharmacological Anxiolysis With Promethazine as an Adjunctive Therapy for Acute Low Back Pain in the Adult Emergency Department Unknown status NCT01129934 Phase 4 Morphine-Promethazine;morphine
42 The ED50 of DEX for Providing Sedation in Different Female Age Group Unknown status NCT02773017 Phase 4 Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
43 Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Tolerability of the Combination of Soy Isoflavones and Red Clover Extract (FITOGYN) in the Treatment of the Hot Flushes in Menopausal Women. Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
44 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
45 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
46 Botulinum A Toxin Intravesical Injections Versus Bladder Overdistension in the Treatment of Patients With Painful Bladder Syndrome: A Prospective Randomized Study Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
47 Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement Unknown status NCT00617500 Phase 4 Hormones
48 Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease Unknown status NCT02940912 Phase 4 Apomorphine;Placebo
49 Prospective Comparative Study of the Efficacy of Common Antipyretic Treatments in Febrile Children Unknown status NCT02294071 Phase 4 Ibuprofen;Acetaminophen
50 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy

Search NIH Clinical Center for Anxiety

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Acetylsalicylic acid
Amobarbital Sodium
Bromodiphenhydramine hydrochloride
buspirone hydrochloride
Chlordiazepoxide Hydrochloride
Chlorpromazine hydrochloride
Clorazepate Dipotassium
Clorazepic acid
Diphenhydramine Citrate
Diphenhydramine Hydrochloride
Doxepin Hydrochloride
Hydroxyzine Hydrochloride
Hydroxyzine Pamoate
Kava preparation
Midazolam Hydrochloride
Nortriptyline Hydrochloride
Prochlorperazine Edisylate Salt
Prochlorperazine Maleate
St. John's Wort

Cochrane evidence based reviews: anxiety disorders

Genetic Tests for Anxiety

Genetic tests related to Anxiety:

# Genetic test Affiliating Genes
1 Anxiety 29 SLC6A4

Anatomical Context for Anxiety

MalaCards organs/tissues related to Anxiety:

Brain, Testes, Breast, Heart, Amygdala, Lung, Prostate

Publications for Anxiety

Articles related to Anxiety:

(show top 50) (show all 42510)
# Title Authors PMID Year
Duplication of GTF2I results in separation anxiety in mice and humans. 38 8
22578324 2012
Amygdalar and hippocampal substrates of anxious temperament differ in their heritability. 38 8
20703306 2010
A key role for orexin in panic anxiety. 38 8
20037593 2010
Familial clustering of major depression and anxiety disorders in Australian and Dutch twins and siblings. 38 8
16354503 2005
Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. 38 8
16244648 2005
Role of the serotonin transporter promoter polymorphism in anxiety-related traits. 38 8
9783565 1998
Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. 38 8
8929413 1996
Pain catastrophizing, anxiety, and depression in hip pathology. 38 17
31256659 2019
Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. 8
21350482 2011
Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene. 8
19693267 2009
Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. 38 88
19370765 2009
Association analysis of monoamine genes with measures of depression and anxiety in a selected community sample of siblings. 8
15729745 2005
A genome scan of neuroticism in nicotine dependent smokers. 8
15389754 2005
Genetic variants implicated in personality: a review of the more promising candidates. 8
15389772 2004
Genome-wide linkage analysis of a composite index of neuroticism and mood-related scales in extreme selected sibships. 8
15351774 2004
Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. 8
15108187 2004
A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. 8
14966478 2004
Linkage analysis of extremely discordant and concordant sibling pairs identifies quantitative-trait loci that influence variation in the human personality trait neuroticism. 8
12612864 2003
Toward a molecular architecture of personality. 8
12642172 2003
Tridimensional personality questionnaire trait of harm avoidance (anxiety proneness) is linked to a locus on chromosome 8p21. 8
12555238 2003
Association and linkage of anxiety-related traits with a functional polymorphism of the serotonin transporter gene regulatory region in Israeli sibling pairs. 8
10822353 2000
An association study of a functional polymorphism of the serotonin transporter gene with personality and psychiatric symptoms. 8
9774781 1998
Anxiety proneness linked to epistatic loci in genome scan of human personality traits. 8
9674977 1998
Why is the recognition rate of psychological distress under-estimated in general hospitals? A cross-sectional observational study in China. 17
31277153 2019
Effect of Qigong on self-rating depression and anxiety scale scores of COPD patients: A meta-analysis. 17
31145299 2019
The CRF system, stress, depression and anxiety-insights from human genetic studies. 9 38
20010888 2010
An association analysis of circadian genes in anxiety disorders. 9 38
20122683 2010
Effect of tryptophan hydroxylase-2 gene variants on amygdalar and hippocampal volumes. 9 38
20331984 2010
A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. 9 38
20075215 2010
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. 9 38
19615387 2010
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. 9 38
19911168 2010
The endocannabinoid system and the treatment of mood and anxiety disorders. 9 38
19839936 2009
The serotonin-1A receptor in anxiety disorders. 9 38
19423077 2009
Soluble corticotropin-releasing hormone receptor 2alpha splice variant is efficiently translated but not trafficked for secretion. 9 38
19520785 2009
Blushing propensity in social anxiety disorder: influence of serotonin transporter gene variation. 9 38
18629430 2009
How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. 9 38
19273493 2009
Research in anxiety disorders: from the bench to the bedside. 9 38
19327970 2009
Sympathetic activity relates to adenosine A(2A) receptor gene variation in blood-injury phobia. 9 38
18629431 2009
Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly. 9 38
19374513 2009
Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. 9 38
19339601 2009
Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. 9 38
19180583 2009
Consequences of post-weaning social isolation on anxiety behavior and related neural circuits in rodents. 9 38
19738931 2009
Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. 9 38
18384079 2008
The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study. 9 38
18603005 2008
The BDNF Val66Met polymorphism and smoking. 9 38
18602452 2008
Role of metabotropic glutamate receptors in the control of neuroendocrine function. 9 38
18616955 2008
5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. 9 38
18047755 2008
Association study between the serotonin 1A receptor (HTR1A) gene and neuroticism, major depression, and anxiety disorders. 9 38
18163385 2008
Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. 9 38
18702710 2008
The role of the glutamatergic system in posttraumatic stress disorder. 9 38
18622363 2008

Variations for Anxiety

ClinVar genetic disease variations for Anxiety:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(6;12)(q14;q24);20p+dn complex Pathogenic
2 46;XX;t(2;11)(q11.2;p13)dn Translocation Pathogenic
3 46;XY;t(2;6)(q33;q21)dn Translocation Pathogenic
4 46;XY;t(1;2)(p34.2;q35)dn Translocation Pathogenic
5 USH2A NM_206933.3(USH2A): c.2299del (p.Glu767fs) deletion Pathogenic/Likely pathogenic rs80338903 1:216420437-216420437 1:216247095-216247095
6 HMBS NM_000190.4(HMBS): c.958del (p.Ala320fs) deletion Likely pathogenic rs1057518806 11:118963865-118963865 11:119093155-119093155
7 OTX2 NM_172337.3(OTX2): c.167_169delinsGG (p.Leu56fs) indel Likely pathogenic rs1555350397 14:57270986-57270988 14:56804268-56804270
8 ADAR NM_001111.5(ADAR): c.1646C> A (p.Ala549Asp) single nucleotide variant Uncertain significance 1:154571017-154571017 1:154598541-154598541
9 USH2A NM_206933.3(USH2A): c.5003G> T (p.Gly1668Val) single nucleotide variant Uncertain significance 1:216258204-216258204 1:216084862-216084862
10 MYH8 NM_002472.3(MYH8): c.5743A> G (p.Ile1915Val) single nucleotide variant Uncertain significance 17:10293842-10293842 17:10390525-10390525

Copy number variations for Anxiety from CNVD:

# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 139649 2 185171337 185512459 Deletion ZNF804A anxiety disorder

Expression for Anxiety

Search GEO for disease gene expression data for Anxiety.

Pathways for Anxiety

Pathways related to Anxiety according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
Show member pathways
2 12.29 TPH2 TPH1 HTR1A CNR1
5 11.76 TSPO HTR1A CNR1
Show member pathways
11.18 TPH2 SLC6A4 MAOA
Show member pathways
10.84 TPH1 MAOA
9 10.55 CNR1 CCKBR
11 10.25 CRHR1 CRH

GO Terms for Anxiety

Biological processes related to Anxiety according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.85 TSPO SLC6A4 HTR2C CRH
2 G protein-coupled receptor signaling pathway GO:0007186 9.76 OPRL1 NPS HTR2C HTR1A CRHR1 CRH
3 steroid metabolic process GO:0008202 9.73 TSPO CYP2D6 CRH
4 circadian rhythm GO:0007623 9.7 TPH2 TPH1 SLC6A4
5 memory GO:0007613 9.65 SLC6A4 CNR1 BDNF
6 response to immobilization stress GO:0035902 9.58 TPH1 CRH
7 adrenal gland development GO:0030325 9.58 TSPO CRH
8 response to pain GO:0048265 9.57 TSPO CRH
9 vasoconstriction GO:0042310 9.54 SLC6A4 HTR1A
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.54 HTR2C HTR1A CNR1
11 parturition GO:0007567 9.49 CRHR1 CRH
12 serotonin receptor signaling pathway GO:0007210 9.46 HTR2C HTR1A
13 negative regulation of voltage-gated calcium channel activity GO:1901386 9.43 OPRL1 CRHR1
14 aromatic amino acid family metabolic process GO:0009072 9.4 TPH2 TPH1
15 serotonin biosynthetic process GO:0042427 9.32 TPH2 TPH1
16 positive regulation of circadian sleep/wake cycle, wakefulness GO:0010841 9.26 NPS CRH
17 regulation of serotonin secretion GO:0014062 8.96 HTR1A CRH
18 behavior GO:0007610 8.8 OPRL1 HTR2C HTR1A
19 signal transduction GO:0007165 10.11 OPRL1 NR3C1 HTR2C HTR1A CRHR1 CRH

Molecular functions related to Anxiety according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.73 OPRL1 HTR2C HTR1A CRHR1 CNR1 CCKBR
2 iron ion binding GO:0005506 9.58 TPH2 TPH1 CYP2D6
3 drug binding GO:0008144 9.5 HTR2C CYP2D6 CNR1
4 myosin binding GO:0017022 9.37 USH2A SLC6A4
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.16 TPH2 TPH1
6 tryptophan 5-monooxygenase activity GO:0004510 8.96 TPH2 TPH1
7 serotonin binding GO:0051378 8.8 SLC6A4 HTR2C HTR1A

Sources for Anxiety

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....